Empagliflozin may decrease risk of kidney stones in diabetics - Video

Published On 2022-06-14T10:00:46+05:30 | Updated On 14 Jun 2022 1:28 PM IST

Overview

We all know that Empagliflozin is the drug used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in people with type 2 diabetes. It is also used to reduce the risk of stroke, heart attack, or death in people who have type 2 diabetes along with heart and blood vessel disease. Also, empagliflozin is used in adults with heart failure to reduce the risk of needing to be hospitalized and death due to heart and blood vessel disease.

Now, this diabetes drug has been found to decrease the risk of kidney stones in patients with type 2 diabetes.

Researchers used existing data from 20 randomized clinical trials to evaluate whether empagliflozin reduced the risk of kidney stones and they pooled data from 15,081 type 2 diabetes patients. Of these, 10,177 received empagliflozin and 4,904 received a placebo.

Patients took either empagliflozin or a placebo for about 1 ½ years. The results of the study showed that when compared with placebo, treatment with empagliflozin was associated with an approximate 40% reduced risk of kidney stones in type 2 diabetes patients. While the precise mechanism is not known, the findings did mean that empagliflozin may be used to prevent kidney stones in individuals with type 2 diabetes.

This study was presented Sunday, June 12 at ENDO 2022, the Endocrine Society's annual meeting in Atlanta, Ga.

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751